Hélène Sicard

In Vivo Immunomanipulation of Vγ9Vδ2 T Cells with a Synthetic Phosphoantigen in a Preclinical Nonhuman Primate Model

Hélène Sicard, Sophie Ingoure, Béatrice Luciani et al. · The Journal of Immunology · 2005 · 185 citations · Full text

Primate Blood, Adaptive Immune System, Immunology +19

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial

M. Bagot, Pierluigi Porcu, Anne Marie‐Cardine et al. · The Lancet Oncology · 2019 · 154 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Autoimmune Disease +8

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

Julie Gertner-Dardenne, Cécile Bonnafous, Christine Bezombes et al. · Blood · 2009 · 139 citations · Full text

Healthy Subjects, Immunotoxicology, Apoptosis +19

Phosphoantigen/IL2 Expansion and Differentiation of Vγ2Vδ2 T Cells Increase Resistance to Tuberculosis in Nonhuman Primates

Crystal Y. Chen, Shuyu Yao, Dan Huang et al. · PLoS Pathogens · 2013 · 123 citations · Full text

Lymphocyte Development, Adaptive Immune System, Immunodeficiencies +21

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors

Jaafar Bennouna, Vincent Lévy, Hélène Sicard et al. · Cancer Immunology Immunotherapy · 2010 · 100 citations · Full text

Cancer Immunosurveillance, Solid Tumors, Immunology +8